KR20220139443A - 항-egfr 항체 약물 접합체 제형 - Google Patents

항-egfr 항체 약물 접합체 제형 Download PDF

Info

Publication number
KR20220139443A
KR20220139443A KR1020227034264A KR20227034264A KR20220139443A KR 20220139443 A KR20220139443 A KR 20220139443A KR 1020227034264 A KR1020227034264 A KR 1020227034264A KR 20227034264 A KR20227034264 A KR 20227034264A KR 20220139443 A KR20220139443 A KR 20220139443A
Authority
KR
South Korea
Prior art keywords
formulation
adc
egfr
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227034264A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 최페
카타리나 칼레타
비닛 쿠마
Original Assignee
아비에 도이치란트 게엠베하 운트 콤파니 카게
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아비에 도이치란트 게엠베하 운트 콤파니 카게, 애브비 인코포레이티드 filed Critical 아비에 도이치란트 게엠베하 운트 콤파니 카게
Publication of KR20220139443A publication Critical patent/KR20220139443A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227034264A 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형 Withdrawn KR20220139443A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361790490P 2013-03-15 2013-03-15
US61/790,490 2013-03-15
PCT/US2014/027868 WO2014143765A1 (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations
KR1020227009445A KR20220041957A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009445A Division KR20220041957A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형

Publications (1)

Publication Number Publication Date
KR20220139443A true KR20220139443A (ko) 2022-10-14

Family

ID=50680154

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227034264A Withdrawn KR20220139443A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형
KR1020157029907A Expired - Fee Related KR102305226B1 (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형
KR1020217029935A Withdrawn KR20210118238A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형
KR1020227009445A Withdrawn KR20220041957A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020157029907A Expired - Fee Related KR102305226B1 (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형
KR1020217029935A Withdrawn KR20210118238A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형
KR1020227009445A Withdrawn KR20220041957A (ko) 2013-03-15 2014-03-14 항-egfr 항체 약물 접합체 제형

Country Status (28)

Country Link
US (2) US20140286969A1 (enExample)
EP (2) EP2968588B1 (enExample)
JP (4) JP6382935B2 (enExample)
KR (4) KR20220139443A (enExample)
CN (2) CN105163763B (enExample)
AU (4) AU2014228172B2 (enExample)
BR (1) BR112015023391A8 (enExample)
CA (1) CA2906130A1 (enExample)
CY (1) CY1121949T1 (enExample)
DK (1) DK2968588T3 (enExample)
ES (1) ES2727134T3 (enExample)
HK (1) HK1219044A1 (enExample)
HR (1) HRP20190672T1 (enExample)
HU (1) HUE044071T2 (enExample)
IL (2) IL241009A0 (enExample)
LT (1) LT2968588T (enExample)
ME (1) ME03457B (enExample)
MX (2) MX2015012549A (enExample)
NZ (1) NZ630826A (enExample)
PL (1) PL2968588T3 (enExample)
PT (1) PT2968588T (enExample)
RS (1) RS58666B1 (enExample)
RU (2) RU2015144287A (enExample)
SG (2) SG10201707633VA (enExample)
SI (1) SI2968588T1 (enExample)
TR (1) TR201905313T4 (enExample)
TW (3) TW202146054A (enExample)
WO (1) WO2014143765A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
SI2668209T1 (sl) 2011-01-24 2021-05-31 Gilead Sciences, Inc. Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2017051254A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
CA3006249A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2017089894A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
RU2740996C2 (ru) * 2016-05-17 2021-01-22 Эббви Байотерапьютикс Инк. КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3468616A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
WO2018223958A1 (zh) * 2017-06-06 2018-12-13 江苏恒瑞医药股份有限公司 一种含c-Met抗体药物偶联物的药物组合物及其用途
KR20250004902A (ko) * 2017-08-23 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3790591A4 (en) 2018-05-09 2022-05-11 LegoChem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
DK3852617T3 (da) * 2018-09-20 2025-10-20 Sfj Pharma X Inc Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
WO2020180967A1 (en) * 2019-03-04 2020-09-10 Amgen Inc. In vivo reversibility of high molecular weight species
PT3811979T (pt) * 2019-03-26 2024-01-02 Remegen Co Ltd Preparação farmacêutica de conjugado fármaco anticorpo anti-her2
WO2020233534A1 (zh) * 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
JP7303298B2 (ja) * 2019-08-07 2023-07-04 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 抗体薬物複合体及びその応用
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
CN112516090B (zh) * 2019-09-18 2023-06-20 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
KR20220157998A (ko) * 2020-03-25 2022-11-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체 약물 접합체를 포함하는 약학적 조성물 및 이의 용도
CA3175181A1 (en) * 2020-04-10 2021-10-14 Aditya Kulkarni Hydroxyureamethyl-acylfulvene for treating brain cancer or cns cancer
CN116761632A (zh) * 2020-11-11 2023-09-15 加图立大学校产学协力团 用于增强靶向治疗剂的治疗效果的基于抗体的缀合物
US20240000961A1 (en) * 2020-11-11 2024-01-04 The Catholic University Of Korea Industry-Academic Cooperation Foundation Antibody-based conjugate for enhancing therapeutic effect of targeted therapeutic agent
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN115300623B (zh) * 2021-05-08 2024-06-21 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
EP4337676A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN115721732B (zh) * 2021-08-27 2025-03-07 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合物、制剂及其制备方法、用途
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
CN119654161A (zh) * 2022-06-10 2025-03-18 艾瑟林公司 抗igf-1r抗体组合物
CA3258214A1 (en) * 2022-06-15 2025-03-18 Jiangsu Hansoh Pharmaceutical Group Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND ITS USE
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
TW202523354A (zh) * 2023-11-29 2025-06-16 大陸商四川科倫博泰生物醫藥股份有限公司 抗體製劑

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
ATE207366T1 (de) * 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP2002513402A (ja) 1997-02-25 2002-05-08 アリゾナ ボード オブ リーゼンツ 細胞増殖抑制性の鎖状および環状デプシペプチドであるドラスタチン１６、ドラスタチン１７およびドラスタチン１８の単離と構造決定
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004074163A1 (en) * 2003-02-14 2004-09-02 Rubbermaid Commercial Products Llc Liquid dispenser
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
ES2549077T3 (es) * 2004-04-07 2015-10-22 Genentech, Inc. Espectrometría de masas de conjugados de anticuerpos
BRPI0516284A (pt) * 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
BR112012004710A2 (pt) * 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201201835A (en) * 2010-03-17 2012-01-16 Abbott Res Bv Anti-nerve growth factor (NGF) antibody compositions
KR20130060223A (ko) * 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
BR112015023520A2 (pt) * 2013-03-15 2017-10-24 Abbvie Inc purificação do conjugado de anticorpo-fármaco (adc)
HRP20210953T1 (hr) * 2014-02-18 2021-09-03 Illumina, Inc. Postupci i pripravci za određivanje dnk profila

Also Published As

Publication number Publication date
JP2020143152A (ja) 2020-09-10
AU2014228172B2 (en) 2018-12-06
BR112015023391A2 (pt) 2017-11-28
CA2906130A1 (en) 2014-09-18
AU2023200432A1 (en) 2023-03-02
KR20210118238A (ko) 2021-09-29
WO2014143765A8 (en) 2015-09-11
TR201905313T4 (tr) 2019-05-21
HK1219044A1 (zh) 2017-03-24
CN110433139A (zh) 2019-11-12
AU2014228172A1 (en) 2015-09-24
NZ630826A (en) 2017-06-30
PL2968588T3 (pl) 2019-08-30
WO2014143765A1 (en) 2014-09-18
JP6382935B2 (ja) 2018-08-29
AU2020277164A1 (en) 2020-12-24
EP2968588B1 (en) 2019-01-09
IL274881A (en) 2020-07-30
RS58666B1 (sr) 2019-06-28
CY1121949T1 (el) 2020-10-14
SG10201707633VA (en) 2017-11-29
EP2968588A1 (en) 2016-01-20
RU2020125266A (ru) 2020-09-24
DK2968588T3 (en) 2019-04-23
TW201945032A (zh) 2019-12-01
US20140286969A1 (en) 2014-09-25
CN105163763B (zh) 2019-07-02
PT2968588T (pt) 2019-05-08
EP3517132A1 (en) 2019-07-31
JP2018184468A (ja) 2018-11-22
SG11201507430RA (en) 2015-10-29
LT2968588T (lt) 2019-05-10
BR112015023391A8 (pt) 2018-01-30
US20200282072A1 (en) 2020-09-10
KR20150131366A (ko) 2015-11-24
TW202146054A (zh) 2021-12-16
HUE044071T2 (hu) 2019-09-30
AU2018267662A1 (en) 2018-12-13
MX2020000333A (es) 2020-07-13
CN105163763A (zh) 2015-12-16
RU2015144287A (ru) 2017-04-24
ES2727134T3 (es) 2019-10-14
TWI689313B (zh) 2020-04-01
TW201519903A (zh) 2015-06-01
IL241009A0 (en) 2015-11-30
KR20220041957A (ko) 2022-04-01
SI2968588T1 (sl) 2019-05-31
HRP20190672T1 (hr) 2019-08-23
RU2015144287A3 (enExample) 2018-03-19
JP2016515511A (ja) 2016-05-30
HK1217644A1 (en) 2017-01-20
ME03457B (me) 2020-01-20
JP2022126754A (ja) 2022-08-30
NZ732015A (en) 2022-01-28
MX2015012549A (es) 2016-06-21
KR102305226B1 (ko) 2021-09-29

Similar Documents

Publication Publication Date Title
KR102305226B1 (ko) 항-egfr 항체 약물 접합체 제형
RU2740996C2 (ru) КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20190262417A1 (en) Antibody drug conjugate (adc) purification
AU2016365117A1 (en) Anti-huLRRC15 antibody drug conjugates and methods for their use
HK40012192A (en) Anti-egfr antibody drug conjugate formulations
NZ732015B2 (en) Anti-EGFR antibody drug conjugate formulations
HK1217644B (en) Anti-egfr antibody drug conjugate formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000